Irland - Englisch - HPRA (Health Products Regulatory Authority)

abbott laboratories ireland ltd - clarithromycin - film coated tablet - 250 milligram

Irland - Englisch - HPRA (Health Products Regulatory Authority)

abbott laboratories ireland ltd - clarithromycin - film coated tablet - 500 milligram

Irland - Englisch - HPRA (Health Products Regulatory Authority)

g & a licensing limited - clarithromycin - film coated tablet - 500 milligram

Irland - Englisch - HPRA (Health Products Regulatory Authority)

imbat limited - clarithromycin - film coated tablet - 500 milligram - macrolides

Armenien - Englisch - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

aesica queenborough limited - clarithromycin - tablets modified-release film-coated - 500mg

Malta - Englisch - Medicines Authority

mylan products limited - clarithromycin - coated tablet - clarithromycin 250 mg - antibacterials for systemic use

Irland - Englisch - HPRA (Health Products Regulatory Authority)

pco manufacturing - clarithromycin - film coated tablet - 250 milligram

Irland - Englisch - HPRA (Health Products Regulatory Authority)

imbat limited - clarithromycin - film coated tablet - 250 milligram - macrolides

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - dasatinib, quantity: 70 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; hyprolose; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - sprycel is indicated for the treatment of adults aged 18 years or over with: - newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. - chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukameia with resistance or intolerance to prior therapy including imatinib. - newly diagnosed philadelphia chromosome positive acute lymphoblastic leukameia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukamia with resistance or intolerance to prior therapy.,sprycel is indicated for the treatment of paediatric patients with: - ph+ cml in the chronic phase. - newly diagnosed ph+ all in combination with chemotherapy.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - sprycel is indicated for the treatment of adults aged 18 years or over with: - newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. - chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukameia with resistance or intolerance to prior therapy including imatinib. - newly diagnosed philadelphia chromosome positive acute lymphoblastic leukameia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukamia with resistance or intolerance to prior therapy.,sprycel is indicated for the treatment of paediatric patients with: - ph+ cml in the chronic phase. - newly diagnosed ph+ all in combination with chemotherapy.